<DOC>
	<DOCNO>NCT00659399</DOCNO>
	<brief_summary>The purpose study assess feasibility safety use daily Fondaparinux Sodium ( ARIXTRA® ) patient ovarian cancer 'clinical remission ' ( clinical evidence disease ) chemotherapy high risk ovarian cancer recurrence .</brief_summary>
	<brief_title>Feasibility Study Short Term Fondaparinux ( Arixtra ) Chemotherapy-Pretreated Ovarian Carcinoma Patients High Risk Progression</brief_title>
	<detailed_description>Rationale : A large body work support association abnormal coagulation ( blood clot formation ) malignancy . A coagulation enzyme thrombin able 1 ) enhance cancer cell adhesion platelets endothelial cell 2 ) stimulate tumor cell growth , 3 ) increase metastasis 4 ) stimulate tumor angiogenesis . Thrombin inhibition anti-metastatic anti-tumor activity mouse model . Recent meta-analysis 4 major randomize clinical trial evaluate effect anticoagulant overall survival cancer patient compare low molecular weight heparin ( LMWH ) placebo demonstrate 13 % risk reduction mortality 1 year 10 % risk reduction 2 year , statistically significant independent potential confound effect anticoagulation prevention venous thromboembolic disease . Fondaparinux sodium ( ARIXTRA® ) highly effective newer anticoagulant fully synthetic pentasaccharide . Arixtra bind antithrombin III subsequently inhibit Factor Xa hence thrombin generation . Arixtra excellent safety profile clinical trial 10,000 patient . When compare LMWHs , ARIXTRA® potential pharmacokinetic advantage base longer half-life 16-17 hour . Hypothesis : The hypothesis test whether completion 8 week ARIXTRA® patient ovarian cancer 'clinical remission ' ( clinical evidence disease ) chemotherapy high risk ovarian cancer recurrence feasible safe inhibition thrombin generation ARIXTRA® ovarian cancer result decrease ovarian cancer recurrence . A concise description methodology : The trial prospective open-label cohort feasibility study give 2 month ARIXTRA® patient high risk recurrence ovarian cancer . The planned accrual 15 patient . Patients treat fix dose ARIXTRA® 2.5 mg subcutaneous injection daily . Treatment continue 2 month disease recurrence grade 3 adverse event patient refusal . In addition , patient follow survival recurrence .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Fondaparinux</mesh_term>
	<mesh_term>PENTA</mesh_term>
	<criteria>Patients 18 year age ≤75 year age Biopsyproven ovarian , tubal primary peritoneal epithelial adenocarcinoma ; Performance status 0,1 ( ECOG ) ( table 2 ) Patients high risk clinical relapse : first remission stage III/IV suboptimally debulked ( residual disease &gt; 1 cm ) Patients stage recur second chemotherapy induce remission . Clinical remission define : absence symptom may relate disease image without abnormality great equal 1 cm suspicious disease ( ascites ) CA 125 obtain x 1 &lt; 35 units/ml . Adequate end organ function , define follow : Total bilirubin &lt; 1.5 x ULN SGOT SGPT &lt; 2.5 x UNL Creatinine &lt; 1.5 x ULN ANC &gt; 1.5 x 109/L Platelets &gt; 100 x 109/L Weight ≥ 50 kg Patients performance status ECOG =2,3,4 Patients warfarin prior therapeutic anticoagulation Patient another primary malignancy require active intervention within 5 year , exception basal cell skin cancer cervical carcinoma situ . Patient severe and/or uncontrolled medical disease ( i.e. , uncontrolled diabetes , chronic renal disease , active uncontrolled infection ) . Patient major surgery within 2 week prior study entry Patients follow lab abnormality : WBC &lt; 3000 absolute neutrophil count &lt; 1,500 hemoglobin &lt; 10 g/dL platelet &lt; 100,000 creatinine clearance &lt; 30 cc/min serum ALT , AST , total bilirubin &gt; 1.5X upper limit normal Patients know bleed disorder</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Pretreated Ovarian Carcinoma</keyword>
</DOC>